Subtopic Deep Dive

Patent Expiry Effects on Pharmaceuticals
Research Guide

What is Patent Expiry Effects on Pharmaceuticals?

Patent expiry effects on pharmaceuticals examine the economic impacts of patent cliffs, including revenue declines for originators and surges in generic entry leading to price competition.

This subtopic analyzes how patent expiration triggers generic competition, reducing originator revenues by up to 80% within months (Dunne et al., 2013, 214 citations). Studies model lifecycle management strategies amid these transitions across OECD and emerging markets (Belloni et al., 2016, 650 citations; Danzon et al., 2013, 154 citations). Over 50 papers quantify these dynamics using econometric models of market entry and pricing.

Curated Papers

Key Challenges

Why It Matters

Patent cliffs determine pharma profitability, with originators facing sharp revenue drops post-expiry, influencing R&D investment decisions (Dubois et al., 2015, 241 citations). Generic entry lowers prices by 30-90%, enhancing access in low-income settings but challenging originator recovery strategies (Danzon et al., 2013). Policymakers use these insights for pricing reforms, as seen in OECD analyses of spending controls (Belloni et al., 2016). Lifecycle models inform evergreening tactics amid rising drug costs (van der Gronde et al., 2017).

Key Research Challenges

Quantifying Revenue Loss

Models struggle to isolate patent expiry effects from confounding factors like marketing or parallel imports. Econometric approaches often rely on pre-post comparisons with limited controls (Berndt, 2002). Recent work highlights data gaps in global generic penetration rates (Dunne et al., 2013).

Generic Entry Timing

Predicting exact generic launch dates amid litigation and regulatory delays remains imprecise. Studies across eight countries reveal policy variances delaying competition (Hassali et al., 2013). Heterogeneity in emerging markets complicates forecasts (Danzon et al., 2013).

Lifecycle Management Efficacy

Assessing strategies like reformulations or new indications for extending exclusivity faces endogeneity issues. High-priced precision drugs post-expiry amplify cost pressures (van der Gronde et al., 2017). Competitive dynamics vary by market size and innovation incentives (Dubois et al., 2015).

Essential Papers

Pharmaceutical Expenditure And Policies

Annalisa Belloni, David Morgan, Valérie Paris · 2016 · OECD health working papers · 650 citations

Across OECD countries, pharmaceutical spending reached around USD 800 billion in 2013, accounting for about 20% of total health spending on average when pharmaceutical consumption in hospital is ad...

Market size and pharmaceutical innovation

Pierre Dubois, Olivier de Mouzon, Fiona M. Scott-Morton et al. · 2015 · The RAND Journal of Economics · 241 citations

This article quantifies the relationship between market size and innovation in the pharmaceutical industry using improved, and newer, methods and data. We find significant elasticities of innovatio...

A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study

Suzanne S. Dunne, Bill Shannon, Colum Dunne et al. · 2013 · BMC Pharmacology and Toxicology · 214 citations

What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs

Suzanne S. Dunne, Colum Dunne · 2015 · BMC Medicine · 183 citations

Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price

Ernst R. Berndt · 2002 · The Journal of Economic Perspectives · 169 citations

The U.S. pharmaceutical industry has again become the focus of considerable controversy. In understanding the economics underlying this industry, distinctions between short, medium and long-run cos...

Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement

Patricia M. Danzon, Andrew Mulcahy, Adrian Towse · 2013 · Health Economics · 154 citations

Abstract This paper analyzes determinants of ex‐manufacturer prices for originator and generic drugs across countries. We focus on drugs to treat HIV/AIDS, TB, and malaria in middle and low‐income ...

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

Brian Godman, Anna Bucsics, Patricia Vella Bonanno et al. · 2018 · Frontiers in Public Health · 152 citations

<b>Introduction:</b> There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challeng...

Reading Guide

Foundational Papers

Start with Berndt (2002) for US price-quantity basics, then Dunne et al. (2013) for generic economic benefits case study, and Danzon et al. (2013) for cross-country pricing models.

Recent Advances

Belloni et al. (2016) on OECD expenditures; Dubois et al. (2015) on market size-innovation links; van der Gronde et al. (2017) on high-price lifecycle challenges.

Core Methods

Difference-in-differences for expiry impacts; elasticity estimations from market size data; panel regressions on originator-generic price transitions.

How PapersFlow Helps You Research Patent Expiry Effects on Pharmaceuticals

Discover & Search

Research Agent uses searchPapers and exaSearch to find 200+ papers on 'patent cliff revenue models', then citationGraph on Belloni et al. (2016) reveals clusters in OECD policy effects. findSimilarPapers expands to generics studies like Dunne et al. (2013).

Analyze & Verify

Analysis Agent runs readPaperContent on Danzon et al. (2013) to extract pricing elasticities, verifies claims with CoVe against raw data, and uses runPythonAnalysis for regression replication on generic penetration stats with GRADE scoring for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in lifecycle models post-Dubois et al. (2015), flags contradictions in generic perception studies (Dunne and Dunne, 2015), while Writing Agent applies latexEditText and latexSyncCitations for policy report drafting with exportMermaid for competition flowcharts.

Use Cases

"Plot generic price drops after Lipitor patent expiry using real data."

Research Agent → searchPapers('atorvastatin generic entry') → Analysis Agent → runPythonAnalysis(pandas/matplotlib on extracted price series) → matplotlib price decline graph with 85% drop visualization.

"Draft LaTeX section on EU patent cliff policies citing OECD data."

Synthesis Agent → gap detection on Belloni et al. (2016) → Writing Agent → latexEditText + latexSyncCitations(10 refs) → latexCompile → PDF with formatted tables on spending impacts.

"Find GitHub code for pharma patent expiry simulations."

Research Agent → paperExtractUrls(Dubois et al., 2015) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Python model for market size elasticities.

Automated Workflows

Deep Research workflow scans 50+ papers on generic policies via searchPapers → citationGraph → structured report on expiry effects (Hassali et al., 2013). DeepScan applies 7-step CoVe to verify revenue models in Berndt (2002) with GRADE checkpoints. Theorizer generates hypotheses on post-expiry R&D from Dubois et al. (2015) clusters.

Try Doxa for Patent Expiry Effects on Pharmaceuticals Research

Frequently Asked Questions

What defines patent expiry effects in pharma?

Patent expiry ends originator exclusivity, enabling generic entry that slashes prices and originator revenues by 70-90% within a year (Dunne et al., 2013).

What methods analyze these effects?

Econometric models estimate entry elasticities and revenue trajectories using pre-post expiry data, often with instrumental variables for endogeneity (Danzon et al., 2013; Dubois et al., 2015).

What are key papers?

Belloni et al. (2016, 650 citations) reviews OECD spending post-expiry; Dunne et al. (2013, 214 citations) quantifies Irish generic savings; Berndt (2002, 169 citations) models US quantity-price dynamics.

What open problems exist?

Predicting multi-country generic delays amid litigation; evaluating evergreening ROI; modeling precision medicine cliffs under orphan policies (van der Gronde et al., 2017).